Cargando…
Registry-based study in people with cystic fibrosis and an R117H variant treated with ivacaftor
BACKGROUND: Ivacaftor approval was extended to people with cystic fibrosis (CF) and an R117H variant in 2014 in the USA. This observational, real-world, postapproval study evaluated long-term outcomes among people with CF and an R117H variant on ivacaftor using data from the US Cystic Fibrosis Found...
Autores principales: | Higgins, Mark, Farietta, Thalia, Campbell, Daniel, Liu, Meng, Ostrenga, Josh, Elbert, Alexander, Shih, Judy, Volkova, Nataliya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10231020/ https://www.ncbi.nlm.nih.gov/pubmed/37230763 http://dx.doi.org/10.1136/bmjresp-2022-001447 |
Ejemplares similares
-
Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor
por: Bessonova, Leona, et al.
Publicado: (2018) -
Lung function in children with cystic fibrosis in the USA and UK: a comparative longitudinal analysis of national registry data
por: Schlüter, Daniela K, et al.
Publicado: (2022) -
ROCK STUDY in CF: sustained anti-inflammatory effects of lumacaftor–ivacaftor in sputum and peripheral blood samples of adult patients with cystic fibrosis—an observational study
por: Arooj, Parniya, et al.
Publicado: (2023) -
Exploring the impact of elexacaftor-tezacaftor-ivacaftor treatment on opinions regarding airway clearance techniques and nebulisers: TEMPO a qualitative study in children with cystic fibrosis, their families and healthcare professionals
por: Almulhem, Maryam, et al.
Publicado: (2022) -
Acceptability of patient reported outcome measures (PROMs) in a cystic fibrosis data registry
por: Ratnayake, Irushi, et al.
Publicado: (2021)